Major depressive disorder
Conditions
Interventions
SSRI treatment effective group:NA
5-Methyltetrahydrofolate Intervention Group:Supplement 5-methyltetrahydrofolate to individuals carrying the MTHFR risk allele, conduct a 6-week intervention, assess the degree of depression improvemen
Sponsors
Beijing Anding Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Sample Inclusion Criteria: 1. The informed consent has been signed, and all assessments have been completed. 2. Assessed using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Patient Edition (SCID-I/P), meeting the DSM-IV diagnostic criteria for depression. 3. HAMD-17 score >= 17. 4. Age between 18-60 years, no gender restriction. 5. History of SSRI medication treatment. SSRI Resistance Screening Criteria: Ineffectiveness of SSRI treatment at adequate dosage and duration. Specifically: 1. Medication dosage >= fluoxetine 40mg/day or its equivalent (sertraline >= 100mg/day, paroxetine >= 30mg/day, escitalopram >= 15mg/day, citalopram >= 40mg/day). 2. Each medication used for no less than 6 weeks (>=6 weeks). 3. Criteria for poor final treatment response: HAMD-17 total score reduction rate from baseline < 25%. SSRI Treatment Efficacy Screening Criteria: Taking SSRI medication for at least 6 weeks, with a HAMD-17 total score <= 7 after treatment, is considered effective SSRI treatment.
Exclusion criteria
Exclusion criteria: 1. Comorbidity with other mental disorders. 2. History of traumatic brain injury, epilepsy, or other known organic diseases of the central nervous system. 3. Presence of, or history of, severe or unstable physical diseases. 4. Substance dependence or abuse, or mental disorders induced by psychoactive substances. 5. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Peripheral Blood DNA Methylation Levels;response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| MTHFR gene polymorphism;Target gene methylation level;Difference in QIDS-SR score reduction between the two groups; | — |
Countries
China
Contacts
Public ContactNan Lyu
Beijing Anding Hospital, Capital Medical University
Outcome results
None listed